IGCS 2021 - Annual Global Meeting of the International Gynecologic Cancer Society (Virtual Meeting)
Aug 30 - Sep 02, 2021 | RomeItaly
LARVOL is not affiliated with Annual Global Meeting of the International Gynecologic Cancer Society (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners
Showing 30 abstracts linked to Trials
[VIRTUAL] DOES INTENSIVE FOLLOW-UP IMPROVE OVERALL SURVIVAL IN ENDOMETRIAL CANCER PATIENTS? RESULTS FROM THE TOTEM RANDOMIZED CONTROLLED TRIAL.
[VIRTUAL] EMPOWER-CERVICAL 1/GOG-3016/ENGOT-CX9: RESULTS OF PHASE 3 TRIAL OF CEMIPLIMAB VS INVESTIGATOR’S CHOICE CHEMOTHERAPY IN RECURRENT/METASTATIC CERVICAL CARCINOMA
[VIRTUAL] EFFICACY AND SAFETY OF NIRAPARIB MAINTENANCE TREATMENT IN PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER AFTER SHORTER OR LONGER CHEMOTHERAPY: A POST HOC SUBGROUP ANALYSIS
[VIRTUAL] COST-EFFECTIVENESS OF DOSTARLIMAB IN ADVANCED RECURRENT DEFICIENT MISMATCH REPAIR ENDOMETRIAL CANCER PATIENTS
[VIRTUAL] RANDOMIZED PHASE 3 STUDY OF LENVATINIB PLUS PEMBROLIZUMAB FOR ADVANCED ENDOMETRIAL CANCER (AEC): SUBGROUP ANALYSIS OF PATIENTS WITH DNA MISMATCH REPAIR DEFICIENT (DMMR) TUMORS
[VIRTUAL] ANTITUMOR ACTIVITY OF DOSTARLIMAB IN PATIENTS WITH ADVANCED OR RECURRENT MISMATCH REPAIR–DEFICIENT OR PROFICIENT–CANCER BY PRIOR THERAPY: RESULTS FROM THE GARNET STUDY
[VIRTUAL] TISOTUMAB VEDOTIN (TV) + BEVACIZUMAB OR PEMBROLIZUMAB OR CARBOPLATIN IN RECURRENT/METASTATIC CERVICAL CANCER (R/MCC): PHASE 1B/2 ENGOT-CX8/GOG-3024/INNOVATV 205 STUDY DOSE-ESCALATION RESULTS
[VIRTUAL] EFFICACY AND SAFETY OF SOCAZOLIMAB IN RECURRENT OR METASTATIC CERVICAL CANCER: RESULTS FROM THE PHASE I TRIAL FOLLOWED BY AN EXPANSION STUDY
[VIRTUAL] CLINICAL AND MOLECULAR CHARACTERISTICS OF ARIEL3 PATIENTS WHO DERIVED EXCEPTIONAL BENEFIT FROM RUCAPARIB MAINTENANCE TREATMENT FOR HIGH-GRADE OVARIAN CANCER (HGOC)
[VIRTUAL] Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer - final analysis
[VIRTUAL] A MULTICENTER, OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY TO COMPARE THE EFFICACY AND SAFETY OF LENVATINIB IN COMBINATION WITH PEMBROLIZUMAB VS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH ADVANCED ENDOMETRIAL CANCER: STUDY 309/KEYNOTE-775
[VIRTUAL] Rucaparib vs chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious BRCA mutation: efficacy and safety from ARIEL4, a randomized phase 3 study
[VIRTUAL] Adjuvant chemotherapy following chemo-radiation as primary treatment for locally advanced cervical cancer compared to chemo-radiation alone: The randomised phase 3 OUTBACK Trial
[VIRTUAL] PHASE I STUDY OF MIRVETUXIMAB SORAVTANSINE (MIRV) AND RUCAPARIB FOR RECURRENT ENDOMETRIAL, OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER
[VIRTUAL] EUROPEAN NETWORK FOR GYNAECOLOGICAL ONCOLOGICAL TRIAL (ENGOT)- CX11/GYNECOLOGIC ONCOLOGY GROUP (GOG) 3047/KEYNOTE-A18: PHASE 3 TRIAL OF PEMBROLIZUMAB PLUS CHEMORADIOTHERAPY IN HIGH-RISK LOCALLY ADVANCED CERVICAL CANCER